报价延迟最少15分钟:2026/03/28 09:59 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.28 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.02/0.13
|
|
企业价值
1.04B
|
| 资产负债 |
|
每股账面净值
-0.17
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
348.97M
|
|
每股收益
0.57
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Companyis currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. |
